VERA
What one share of Vera Therapeutics holds
Pharmaceutical Preparations
We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Vera Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.89 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.97 |
| Cash and investments | $6.93 |
| Debt | $1.04 |
| Book value | $5.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$166.93 | $0.31 | −$109.10 | — | −$279.24 |
| 2021 | — | −$2.43 | $0.00 | −$1.76 | — | $5.18 |
| 2022 | — | −$3.35 | $0.00 | −$2.55 | — | $2.89 |
| 2023 | — | −$2.25 | $0.00 | −$2.16 | — | $2.38 |
| 2024 | — | −$2.75 | $0.02 | −$2.45 | — | $10.43 |
| 2025 | — | −$4.66 | $0.01 | −$3.76 | — | $9.41 |